HCC CTC Detection via ASGPR EpCAM Vimentin Profiling

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current diagnostic technologies fail to accurately predict hepatocellular carcinoma (HCC) recurrence or metastasis, leading to significant mortality and loss of donor allografts, as they rely on inadequate radiological staging criteria and inefficient CTC capture methods.

Innovation Solution

A method involving the isolation of circulating tumor cells (CTCs) from blood using capture antibodies specific to asialoglycoprotein receptor (ASGPR), Glypican-3, and epithelial cell adhesion molecule (EpCAM), followed by vimentin binding and enumeration, to detect HCC recurrence or metastasis, with a status score guiding transplant or treatment decisions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If radiological staging criteria are used to select HCC candidates for liver transplantation, then the selection process is simple and quick, but the accuracy of predicting recurrence or metastasis is insufficient

Engineering Contradiction:

Improveaccuracy of predicting recurrence or metastasisVSAvoidcomplexity of diagnostic technology

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent uses circulating tumor cells (CTCs) as an intermediary biomarker to bridge the gap between simple radiological staging and accurate metastasis prediction. CTCs serve as a measurable intermediary that provides direct evidence of tumor presence in circulation, thereby improving predictive accuracy without requiring complex surgical pathology

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces the mechanical/radiological imaging system with a biological detection system based on immunocytology. Instead of relying on radiological criteria that infer tumor status, the system directly detects tumor cells in blood using antibody-based capture and staining methods, substituting indirect mechanical detection with direct biological detection

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Measurement precision

If single-marker CTC capture methods are used, then the assay is simple to perform, but the capture efficiency and sensitivity are insufficient

Engineering Contradiction:

Improvecapture efficiency of CTCsVSAvoidcomplexity of antibody panel

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent merges multiple antibody markers (EpCAM, ASGPR, GPC3) into a single capture assay system. By combining these markers on the same capture platform, the method achieves higher capture efficiency and sensitivity while maintaining operational simplicity through a unified assay protocol

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The patent employs a composite antibody panel consisting of multiple different antibodies targeting different HCC-specific markers. This composite approach leverages the complementary specificities of each antibody to capture a broader range of CTCs, including those that may have lost expression of individual markers

Inventive Principle:

Principle #40Composite materials

3Reliability

If vimentin-positive CTC enumeration is performed, then the ability to detect aggressive disease is improved, but the time and resources required for analysis increase

Engineering Contradiction:

Improveability to detect aggressive or occult metastatic diseaseVSAvoidtime required for CTC analysis

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent performs preliminary enrichment of CTCs using capture antibodies before the vimentin staining step. This preliminary capture action concentrates the rare CTCs from large volumes of blood, making the subsequent vimentin enumeration more efficient and reducing the time required for analysis by eliminating the need to examine entire blood samples

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach effectively discriminates between early-stage and advanced HCC patients, predicting recurrence and survival outcomes, and outperforms existing biomarkers like AFP in detecting advanced disease and guiding treatment.

Implementation Method 1

isolating circulating tumor cells (CTCs) from a blood sample obtained from a subject by contacting the CTCs with a set of capture antibodies, wherein the capture antibodies specifically bind asialoglycoprotein receptor (ASGPR), Glypican-3, and epithelial cell adhesion molecule (EpCAM)

Methodology Applied

Scientific EffectAntibody-antigen binding:

Implementation Method 2

contacting the isolated CTCs with an antibody that specifically binds vimentin

Methodology Applied

Scientific EffectAntibody-antigen binding:

Data Source

PatentEP3676295B1Phenotypic profiling of hepatocellular carcinoma circulating tumor cells for treatment selection

Publication Date: 2023.06.07 RGT UNIV OF CALIFORNIA

Figure 1A~1E
Figure 2A~2B
Figure 3

AI summary

Methods and kits for detecting hepatocellular carcinoma recurrence or metastasis, and of measuring markers of hepatocellular carcinoma, including markers of hepatocellular carcinoma recurrence or metastasis, in a blood sample obtained from a subject by (a) isolating circulating tumor cells (CTCs) by contacting a blood sample obtained from the subject with a set of capture antibodies, wherein the capture antibodies specifically bind asialoglycoprotein receptor (ASGPR), Glypican-3, and epithelial cell adhesion molecule (EpCAM); (b) contacting the isolated CTCs with an antibody that specifically binds vimentin; and (c) measuring the number of vimentin-positive CTC.